Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bisphosphonates Labels Should Discuss Duration Of Use, Advisory Panels Conclude

This article was originally published in The Pink Sheet Daily

Executive Summary

But members of FDA's Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committees acknowledged the lack of definitive evidence on potential risks from long-term use of the osteoporosis drugs.
Advertisement

Related Content

Odanacatib Phase III Success Suggests Merck’s Primary Care Gamble Is Paying Off
Odanacatib Phase III Success Suggests Merck’s Primary Care Gamble Is Paying Off
Drug Safety Business: Start-Up With AERS Filter Eyes Bisphosphonate Events
Drug Safety Business: Start-Up With AERS Filter Eyes Bisphosphonate Events

Topics

Advertisement
UsernamePublicRestriction

Register

PS072866

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel